Cholesterol & Glucomannan
The effects of the soluble fiber konjac glucomannan (GM) on serum cholesterol concentrations were investigated
GM fibers reduced total cholesterol (TC) concentrations by 10%, low-density-lipoprotein cholesterol (LDL-C) concentrations by 7.2%, triglycerides by 23%, and systolic blood pressure by 2.5%. High-density-lipoprotein cholesterol (HDL-C) and the ratio of LDL-C to HDL-C did not change significantly. No change in diastolic blood pressure or body weight was observed. No adverse effects were observed. The results of this study show that GM is an effective cholesterol-lowering dietary adjunct.
Effect of short-term ingestion of konjac glucomannan on serum cholesterol in healthy men. Arvill-A; Bodin-L. Am-J-Clin-Nutr. 1995 Mar; 61(3): 585-9.
Polyactin A is a polysaccharide extracted from cultured alpha-Streptococcus No. 33 in the mouth. It is also known as alpha-glucomannan. According to clinical reports, Polyactin A is considered to be an immunological adjuvant with significant curative effect in chemotherapy of tumors.
Results suggest that polyactin A has a marked immunological activity, which is not entirely due to the role of large molecular weight polysaccharide. It may be an immunological adjuvant and it is experimentally confirmed in mice that Polyactin A can protect the immunity of the organism.
Experimental research on immunological activity of Polyactin A. Zeng-XY. Southeast-Asian-J-Trop-Med-Public-Health. 1993; 24 Suppl 1: 204-5.
Studied behavior in patients (#30) treated for 60 days with a 1.200 kcal (5040 kj) diet plus either placebo or glucomannane. The low-calorie diet plus glucomannane is more effective than the low-calorie diet alone.
[Evaluation of the action of glucomannan on metabolic parameters and on the sensation of satiation in overweight and obese patients] Cairella-M; Marchini-G. Clin-Ter. 1995 Apr; 146(4): 269-74.
Shown the efficacy of long term intermittent administration of a poorly absorbable "antibiotic" (rifaximin) in obtaining symptomatic relief in uncomplicated diverticular disease of the colon.
Outpatients with symptomatic uncomplicated diverticular disease were treated with fibre supplementation (glucomannan 2 g/day) plus rifaximin.
Rifaximin appears to be of some advantage in obtaining symptomatic relief in diverticular disease of the colon when compared with fibre supplementation alone.
Efficacy of rifaximin in the treatment of symptomatic diverticular disease of the colon. A multicentre double-blind placebo-controlled trial. Papi-C; Ciaco-A; Koch-M; Capurso-L. Aliment-Pharmacol-Ther. 1995 Feb; 9(1): 33-9.
Type 2 Diabetes (Glucomannan)
Type 2 diabetes
Glucomannan fiber, in addition to conventional treatment, may improve glycemic control and blood lipid profile among patients with type 2 diabetes. In this study, the researchers determined whether glucomannan facilitated metabolic control in diabetic patients. All eleven patients ate glucomannan fiber-enriched biscuits or placebo wheat bran biscuits during the trial run. Glucomannan fiber reduced these levels: serum fructosamine (5.7%), total HDL cholesterol ratio (10%) and systolic blood pressure (sBP) (6.9%). Based on these results, the researchers concluded that glucomannan may complement conventional treatment for control of type 2 diabetes.
Vuksan V, Jenkins DJ, Spadafora P, Sievenpiper JL, Owen R, Vidgen E, Brighenti F, Josse R, Leiter LA, Bruce-Thompson C: Konjac-mannan (glucomannan) improves glycemia and other associated risk factors for coronary heart disease in type 2 diabetes. A randomized controlled metabolic trial, Diabetes Care 1999 Jun; 22(6): 913-9